COVID-19 Drug Targets Immune Aging, Enters Phase II - Genetic Engineering & Biotechnology News
3/21/2022 12:00:00 AM3 years 1 month ago
by Julianna LeMieux, PhD
by Julianna LeMieux, PhD
A Phase II clinical trial is testing a new drug's ability to reduce mortality in older people hospitalized with COVID-19 by directly targeting immune aging.
Severe COVID-19 infections are more likely in older people, which is likely due to a deterioration of the immune system over time. The need for the development of COVID-19 therapies, especially for a… [+6349 chars]
full article...